Regeneron Pharma (REGN) PT Lowered to $720 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $813.21 -0.01%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 16
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 16
Join SI Premium – FREE
Jefferies analyst Biren Amin lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $720.00 (from $730.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- AMERISAFE (AMSF) PT Lowered to $35 at Citizens on Top and Bottom Line Miss
- HSBC Upgrades FedEx (FDX) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
